Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy

Listeria monocytogenes-Derived Listeriolysin O Has Pathogen-Associated Molecular Pattern-Like Properties Independent of Its Hemolytic Ability

(2012) Anu Wallecha et al.   Clinical and Vaccine Immunology

B7-DC-Ig Enhances Vaccine Effect by a Novel Mechanism Dependent on PD-1 Expression Level on T Cell Subsets

(2012) M. Mkrtichyan et al.   JOURNAL OF IMMUNOLOGY

Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma

(2011) Mikayel Mkrtichyan et al.   CELLULAR IMMUNOLOGY

Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms

(2011) Mikayel Mkrtichyan et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

PD-L2 is expressed on activated human T cells and regulates their function

(2011) Nassima Messal et al.   MOLECULAR IMMUNOLOGY

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix

(2009) Paulo Cesar Maciag et al.   VACCINE